Company

Company Overview

Business Strategy

Location

R&D

Pipeline

Competitiveness

 
Company
 Company Overview
 Business Strategy
 Location
 
Competitiveness
 
  Capability of out-licensing business
  •  Management team with multinational company experience and business success experience
  •  Four overseas, two domestic licensing experience

    - Network for out-license with overseas pharmaceutical companies
    -  Negotiation skills and experience
    -  Signed contract for support of licensed international lawyer and consulting firm

  Securing R & D pipeline with global competitiveness
  •  Pipeline for new drug development: TRPV1 antagonist for neuropathic pain analgesics, TRPV1 agonist for topical pain treatment, Alzheimer's disease modifying drug, early diagnosis kit for Alzheimer's disease, etc.
  •  Several number of candidates for each pipeline
    -  Alzheimer's disease modifying drug: securing four candidate substances
    -  TRPV1 antagonist for neuropathic pain: securing various compound analogues, numerous patent applications
    -  TRPV1 agonist for topical pain treatment: securing various compound analogues, numerous patent applications

2020
Joint research with Quantamatrix for Development of AD Early Diagnosis Kit
2015
Joint research with NIH for topical application of neuropathic pain treatment
2010
Out-license and co-development deal with Roche for Alzheimer's disease treatment
(RAGE modulator)
2008
Joint research and development with Daewoong Pharmaceutical for Alzheimer's disease drug
(Αβ oligomerization inhibitor)
2007
Acute & Chronic Severe Pain Reliever out-licensed to Grünenthal
(Germany)
2005
Non-narcotic strong analgesics out-licensed to Grünenthal
(Germany)